國立虎尾科技大學 |

Valuations of Early-Stage Companies and Disruptive Technologies = How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Valuations of Early-Stage Companies and Disruptive Technologies/ by Tiran Rothman.
Reminder of title:	How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies /
Author:	Rothman, Tiran.
Description:	XII, 219 p. 11 illus., 5 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Capital investments. -
Online resource:	https://doi.org/10.1007/978-3-030-38847-8
ISBN:	9783030388478

Valuations of Early-Stage Companies and Disruptive Technologies = How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies /
Rothman, Tiran.

Valuations of Early-Stage Companies and Disruptive TechnologiesHow to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies /[electronic resource] :by Tiran Rothman. - 1st ed. 2020. - XII, 219 p. 11 illus., 5 illus. in color.online resource.

Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.

This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.

ISBN: 9783030388478

Standard No.: 10.1007/978-3-030-38847-8doiSubjects--Topical Terms:

584969
Capital investments.

LC Class. No.: HG4028.C4

Dewey Class. No.: 658.154

Valuations of Early-Stage Companies and Disruptive Technologies = How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies /
LDR:03999nam a22003975i 4500 001 1029840
003 DE-He213
005 20201127101152.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030388478 $9 978-3-030-38847-8
024 7 $a 10.1007/978-3-030-38847-8 $2 doi
035 $a 978-3-030-38847-8
050 4 $a HG4028.C4
072 7 $a KFFM $2 bicssc
072 7 $a BUS036000 $2 bisacsh
072 7 $a KFFM $2 thema
082 0 4 $a 658.154 $2 23
100 1 $a Rothman, Tiran. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1326657
245 1 0 $a Valuations of Early-Stage Companies and Disruptive Technologies $h [electronic resource] : $b How to Value Life Science, Cybersecurity and ICT Start-ups, and their Technologies / $c by Tiran Rothman.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Palgrave Macmillan, $c 2020.
300 $a XII, 219 p. 11 illus., 5 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Part I. A Short Overview of Valuations -- Chapter 1. Introduction -- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques -- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances -- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations -- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options -- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations -- Chapter 5. Introduction to Behavioral Finance -- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations -- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream? -- Part IV. An Introduction to Valuations in R&D-Intensive Industries -- Chapter 8. The Pharmaceutical Sector -- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing -- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors -- Part V. Actual Valuations -- Chapter 11. Company A: Pharmaceutical / New Compounds -- Chapter 12. Company B: Pharmaceutical / Biologies -- Chapter 13. Company C: Cybersecurity -- Chapter 14. Company D: Renewable Energy -- Chapter 15. Conclusion.
520 $a This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration.
650 0 $a Capital investments. $3 584969
650 0 $a Risk management. $3 559158
650 0 $a New business enterprises. $3 566880
650 0 $a Management. $3 558618
650 0 $a Industrial management. $3 556510
650 0 $a Computer crimes. $3 564161
650 1 4 $a Investment Appraisal. $3 1107685
650 2 4 $a Risk Management. $3 569483
650 2 4 $a Start-Ups/Venture Capital. $3 1108648
650 2 4 $a Innovation/Technology Management. $3 786196
650 2 4 $a Cybercrime. $3 1109747
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030388461
776 0 8 $i Printed edition: $z 9783030388485
776 0 8 $i Printed edition: $z 9783030388492
856 4 0 $u https://doi.org/10.1007/978-3-030-38847-8
912 $a ZDB-2-HTY
912 $a ZDB-2-SXH
950 $a History (SpringerNature-41172)
950 $a History (R0) (SpringerNature-43722)